Global Transthyretin amyloid cardiomyopathy (ATTR-CM) - 2025 -2033
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Size
The global transthyretin amyloid cardiomyopathy (ATTR-CM) was valued at US$ 2.92 Billion n 2023. The global transthyretin amyloid cardiomyopathy (ATTR-CM) market size reached US$ 4.32 Billion in 2024 and is expected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3% during the forecast period 2025-2033.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Overview
The transthyretin amyloid cardiomyopathy (ATTR-CM) market is witnessing substantial growth, primarily driven by increasing disease awareness, advancements in diagnostic technologies, and the growing availability of novel therapeutics.
Key opportunities in the market include ongoing clinical trials, rising investments in rare disease research, and the expansion of patient access programs, particularly in underserved regions.
North America currently dominates the ATTR-CM market due to early adoption of advanced therapies, robust healthcare infrastructure, and strong presence of key pharmaceutical players. However, the Asia-Pacific region is emerging as the fastest-growing market, supported by rising healthcare expenditure, improving diagnostic capabilities, and growing recognition of amyloidosis-related conditions among clinicians.
Rising prevalence & aging population are significantly driving the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth
The rising prevalence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a key driver of market growth, fueled by advancements in non-invasive diagnostics and improved patient outcomes. Innovations such as technetium pyrophosphate nuclear cardiac imaging now allow for accurate diagnosis without the need for cardiac biopsy, leading to earlier and broader identification of patients. In the U.S. alone, approximately 5,000 to 7,000 new cases are now diagnosed annually.
Studies indicating a prevalence of around 20% in heart failure patients with myocardial wall thickening over 14 mm highlight the growing clinical awareness and diagnostic precision. Together, these factors are driving demand for effective treatment options and expanding the ATTR-CM therapeutics market.
Restraint:
High cost of therapy hampering the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The high cost of therapy remains a significant restraint for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Current approved treatments, such as tafamidis (Vyndaqel/Vyndamax), can cost over $225,000 annually in markets like the U.S., posing a serious financial burden for patients and healthcare systems. Despite insurance coverage, out-of-pocket expenses can be substantial, limiting access, especially for underinsured or elderly patients on fixed incomes.
Moreover, in many low- and middle-income countries, such therapies are either unavailable or unaffordable, further widening the treatment gap. High costs also strain national healthcare budgets, making widespread reimbursement and adoption of advanced therapies challenging. As new therapies enter the market, pricing pressure and demand for cost-effective alternatives may intensify, but until then, affordability remains a major barrier to equitable access and market penetration.
Opportunity:
Expansion into emerging markets are expected to create a lucrative opportunity for the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
Expansion into emerging markets presents a significant opportunity for growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Many developing countries in regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing a rapid increase in aging populations, which directly correlates with a higher incidence of ATTR-CM.
Historically, limited diagnostic infrastructure and low disease awareness have hindered detection and treatment in these areas. However, as healthcare systems in these regions modernize, there is increasing investment in rare disease diagnostics, better access to advanced imaging, and improved training for clinicians.
Moreover, pharmaceutical companies are beginning to target these markets with expanded clinical trials, partnerships, and affordable pricing models. By addressing unmet needs and broadening therapeutic availability, expansion into emerging markets not only improves global patient outcomes but also unlocks new revenue streams and drives sustained market growth.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Segment Analysis
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market is segmented based on type, drug type, distribution channel, and region.
The transthyretin stabilizers in the drug type segment are expected to hold 54.6% of the market share in 2024 in the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The transthyretin stabilizers segment is expected to dominate the market. This dominance is primarily due to the widespread adoption and clinical success of tafamidis (Vyndaqel/Vyndamax), the first FDA-approved drug for ATTR-CM. Its proven efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations has positioned it as the standard of care.
For instance, in July 2023, BridgeBio Pharma announced positive Phase 3 results from its ATTRibute-CM trial evaluating acoramidis, a next-generation, orally-administered transthyretin stabilizer for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The study confirmed both the efficacy and safety of acoramidis, reinforcing its potential as a powerful therapeutic option. As a highly potent small molecule designed to stabilize transthyretin (TTR), acoramidis represents a significant advancement in ATTR-CM treatment. This development further strengthens the competitive landscape of transthyretin stabilizers and supports the continued market dominance of this therapy class.
Additionally, its oral administration route enhances patient compliance compared to more invasive treatments. Strong backing from clinical trials, increasing physician familiarity, and early diagnosis through advanced imaging have further driven the uptake of stabilizer therapies, reinforcing their leading position in the ATTR-CM market.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Geographical Analysis
North America is expected to dominate the global transthyretin amyloid cardiomyopathy (ATTR-CM) market with a 41.2% share in 2024
North America is expected to dominate the transthyretin amyloid cardiomyopathy (ATTR-CM) market, driven by strong clinical research activity, early adoption of advanced therapies, and robust regulatory support. For instance, in February 2024, Ionis Pharmaceuticals and AstraZeneca received Fast Track designation from the U.S. FDA for eplontersen, an investigational RNA-targeted therapy for ATTR-CM, reflecting the region's proactive stance in accelerating drug development for unmet medical needs.
Additionally, in May 2024, BridgeBio Pharma announced positive Phase 3 clinical results for acoramidis during the 2024 International Symposium of Amyloidosis, further underscoring North America’s leadership in ATTR-CM innovation. Coupled with high disease awareness, strong healthcare infrastructure, and favorable reimbursement environments, these advancements solidify North America’s position as the dominant regional market for ATTR-CM therapies.
Asia-Pacific is growing at the fastest pace in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, holding 18.6% of the market share
Asia-Pacific is emerging as the fastest-growing region in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market due to a combination of rising disease awareness, improving diagnostic capabilities, and increasing investments in rare disease treatment. Countries such as Japan, China, and South Korea are witnessing a growing elderly population, creating a larger at-risk patient pool.
Collaborations with local healthcare providers and favorable regulatory reforms aimed at expediting drug approvals are further accelerating the adoption of ATTR-CM therapies in the region. These factors collectively contribute to the region's rapid market expansion and position Asia-Pacific as the fastest-growing market for ATTR-CM treatment.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Competitive Landscape
Top companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) market include Pfizer Inc., Ionis Pharmaceuticals, Inc., among others.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Key Developments
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market, valued at US$ 2.92 Billion in 2023, grew to US$ 4.32 Billion in 2024 and is projected to reach US$ 64.09 Billion by 2033, expanding at a robust CAGR of 35.3% from 2025 to 2033. This rapid growth is driven by advancements in RNAi therapies, transthyretin stabilizers, and non-invasive diagnostic tools such as technetium pyrophosphate imaging. North America currently leads the market, fueled by early adoption of novel treatments, a well-established healthcare infrastructure, and the presence of major pharmaceutical players.
The Asia-Pacific region is witnessing the fastest growth, supported by increasing healthcare spending, improved access to diagnostics, and rising awareness of amyloidosis-related cardiac conditions. Although high treatment costs remain a barrier, ongoing R&D, favorable regulatory designations, and expanding clinical trial activity are bolstering the pipeline and accelerating market expansion globally.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market report delivers a detailed analysis with 60+ key tables, more than 55+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) was valued at US$ 2.92 Billion n 2023. The global transthyretin amyloid cardiomyopathy (ATTR-CM) market size reached US$ 4.32 Billion in 2024 and is expected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3% during the forecast period 2025-2033.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Overview
The transthyretin amyloid cardiomyopathy (ATTR-CM) market is witnessing substantial growth, primarily driven by increasing disease awareness, advancements in diagnostic technologies, and the growing availability of novel therapeutics.
Key opportunities in the market include ongoing clinical trials, rising investments in rare disease research, and the expansion of patient access programs, particularly in underserved regions.
North America currently dominates the ATTR-CM market due to early adoption of advanced therapies, robust healthcare infrastructure, and strong presence of key pharmaceutical players. However, the Asia-Pacific region is emerging as the fastest-growing market, supported by rising healthcare expenditure, improving diagnostic capabilities, and growing recognition of amyloidosis-related conditions among clinicians.
Rising prevalence & aging population are significantly driving the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth
The rising prevalence of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a key driver of market growth, fueled by advancements in non-invasive diagnostics and improved patient outcomes. Innovations such as technetium pyrophosphate nuclear cardiac imaging now allow for accurate diagnosis without the need for cardiac biopsy, leading to earlier and broader identification of patients. In the U.S. alone, approximately 5,000 to 7,000 new cases are now diagnosed annually.
Studies indicating a prevalence of around 20% in heart failure patients with myocardial wall thickening over 14 mm highlight the growing clinical awareness and diagnostic precision. Together, these factors are driving demand for effective treatment options and expanding the ATTR-CM therapeutics market.
Restraint:
High cost of therapy hampering the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The high cost of therapy remains a significant restraint for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Current approved treatments, such as tafamidis (Vyndaqel/Vyndamax), can cost over $225,000 annually in markets like the U.S., posing a serious financial burden for patients and healthcare systems. Despite insurance coverage, out-of-pocket expenses can be substantial, limiting access, especially for underinsured or elderly patients on fixed incomes.
Moreover, in many low- and middle-income countries, such therapies are either unavailable or unaffordable, further widening the treatment gap. High costs also strain national healthcare budgets, making widespread reimbursement and adoption of advanced therapies challenging. As new therapies enter the market, pricing pressure and demand for cost-effective alternatives may intensify, but until then, affordability remains a major barrier to equitable access and market penetration.
Opportunity:
Expansion into emerging markets are expected to create a lucrative opportunity for the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) market
Expansion into emerging markets presents a significant opportunity for growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market. Many developing countries in regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing a rapid increase in aging populations, which directly correlates with a higher incidence of ATTR-CM.
Historically, limited diagnostic infrastructure and low disease awareness have hindered detection and treatment in these areas. However, as healthcare systems in these regions modernize, there is increasing investment in rare disease diagnostics, better access to advanced imaging, and improved training for clinicians.
Moreover, pharmaceutical companies are beginning to target these markets with expanded clinical trials, partnerships, and affordable pricing models. By addressing unmet needs and broadening therapeutic availability, expansion into emerging markets not only improves global patient outcomes but also unlocks new revenue streams and drives sustained market growth.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Segment Analysis
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market is segmented based on type, drug type, distribution channel, and region.
The transthyretin stabilizers in the drug type segment are expected to hold 54.6% of the market share in 2024 in the transthyretin amyloid cardiomyopathy (ATTR-CM) market
The transthyretin stabilizers segment is expected to dominate the market. This dominance is primarily due to the widespread adoption and clinical success of tafamidis (Vyndaqel/Vyndamax), the first FDA-approved drug for ATTR-CM. Its proven efficacy in reducing all-cause mortality and cardiovascular-related hospitalizations has positioned it as the standard of care.
For instance, in July 2023, BridgeBio Pharma announced positive Phase 3 results from its ATTRibute-CM trial evaluating acoramidis, a next-generation, orally-administered transthyretin stabilizer for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The study confirmed both the efficacy and safety of acoramidis, reinforcing its potential as a powerful therapeutic option. As a highly potent small molecule designed to stabilize transthyretin (TTR), acoramidis represents a significant advancement in ATTR-CM treatment. This development further strengthens the competitive landscape of transthyretin stabilizers and supports the continued market dominance of this therapy class.
Additionally, its oral administration route enhances patient compliance compared to more invasive treatments. Strong backing from clinical trials, increasing physician familiarity, and early diagnosis through advanced imaging have further driven the uptake of stabilizer therapies, reinforcing their leading position in the ATTR-CM market.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market, Geographical Analysis
North America is expected to dominate the global transthyretin amyloid cardiomyopathy (ATTR-CM) market with a 41.2% share in 2024
North America is expected to dominate the transthyretin amyloid cardiomyopathy (ATTR-CM) market, driven by strong clinical research activity, early adoption of advanced therapies, and robust regulatory support. For instance, in February 2024, Ionis Pharmaceuticals and AstraZeneca received Fast Track designation from the U.S. FDA for eplontersen, an investigational RNA-targeted therapy for ATTR-CM, reflecting the region's proactive stance in accelerating drug development for unmet medical needs.
Additionally, in May 2024, BridgeBio Pharma announced positive Phase 3 clinical results for acoramidis during the 2024 International Symposium of Amyloidosis, further underscoring North America’s leadership in ATTR-CM innovation. Coupled with high disease awareness, strong healthcare infrastructure, and favorable reimbursement environments, these advancements solidify North America’s position as the dominant regional market for ATTR-CM therapies.
Asia-Pacific is growing at the fastest pace in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, holding 18.6% of the market share
Asia-Pacific is emerging as the fastest-growing region in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market due to a combination of rising disease awareness, improving diagnostic capabilities, and increasing investments in rare disease treatment. Countries such as Japan, China, and South Korea are witnessing a growing elderly population, creating a larger at-risk patient pool.
Collaborations with local healthcare providers and favorable regulatory reforms aimed at expediting drug approvals are further accelerating the adoption of ATTR-CM therapies in the region. These factors collectively contribute to the region's rapid market expansion and position Asia-Pacific as the fastest-growing market for ATTR-CM treatment.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Competitive Landscape
Top companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) market include Pfizer Inc., Ionis Pharmaceuticals, Inc., among others.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Key Developments
- In March 2025, Alnylam Pharmaceuticals announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) for AMVUTTRA (vutrisiran), expanding its use to include the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
- In June 2025, Alnylam Pharmaceuticals announced that the European Commission (EC) approved AMVUTTRA (vutrisiran) for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.
- In September 2022, Intellia Therapeutics and Regeneron Pharmaceuticals reported positive interim Phase 1 results for NTLA-2001, an investigational CRISPR/Cas9-based in vivo gene editing therapy for ATTR amyloidosis. The study included 12 adult patients with ATTR-CM and NYHA Class I–III heart failure, showing promise for single-dose, potentially curative treatment.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market, valued at US$ 2.92 Billion in 2023, grew to US$ 4.32 Billion in 2024 and is projected to reach US$ 64.09 Billion by 2033, expanding at a robust CAGR of 35.3% from 2025 to 2033. This rapid growth is driven by advancements in RNAi therapies, transthyretin stabilizers, and non-invasive diagnostic tools such as technetium pyrophosphate imaging. North America currently leads the market, fueled by early adoption of novel treatments, a well-established healthcare infrastructure, and the presence of major pharmaceutical players.
The Asia-Pacific region is witnessing the fastest growth, supported by increasing healthcare spending, improved access to diagnostics, and rising awareness of amyloidosis-related cardiac conditions. Although high treatment costs remain a barrier, ongoing R&D, favorable regulatory designations, and expanding clinical trial activity are bolstering the pipeline and accelerating market expansion globally.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) market report delivers a detailed analysis with 60+ key tables, more than 55+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Drug Type
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence & Aging Population
3.1.1.2. Ongoing Research & Pipeline Expansion
3.1.1.3. Improved Diagnosis & Awareness
3.1.2. Restraints
3.1.2.1. High Cost of Therapy
3.1.2.2. Limited Global Access
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Gene Editing & Next-Gen Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Pipeline Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Pricing Analysis and Price Dynamics
5. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Familial (hereditary) ATTR-CM*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Wild-type ATTR-CM
6. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY DRUG TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Transthyretin Stabilizers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. RNAi Therapy
6.4. Others
7. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.1.1. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Key Players
10.1.1. Pfizer Inc.*
10.1.1.1. Company Overview
10.1.1.1.1. Product Portfolio
10.1.1.1.2. Product Description
10.1.1.1.3. Product Key Performance Indicators (KPIs)
10.1.1.2. Financial Overview
10.1.1.2.1. Company Revenue
10.1.1.2.2. Geographical Revenue Shares
10.1.1.2.3. Revenue Forecasts
10.1.1.3. Key Developments
10.1.1.3.1. Mergers & Acquisitions
10.1.1.3.2. Key Product Development Activities
10.1.1.3.3. Regulatory Approvals, etc.
10.1.1.4. SWOT Analysis
10.1.2. Ionis Pharmaceuticals, Inc.
10.2. Emerging Players
10.2.1. Arrowhead Pharmaceuticals Inc.
10.2.2. Intellia Therapeutics, Inc.(LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Drug Type
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence & Aging Population
3.1.1.2. Ongoing Research & Pipeline Expansion
3.1.1.3. Improved Diagnosis & Awareness
3.1.2. Restraints
3.1.2.1. High Cost of Therapy
3.1.2.2. Limited Global Access
3.1.3. Opportunity
3.1.3.1. Expansion into Emerging Markets
3.1.3.2. Gene Editing & Next-Gen Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Pipeline Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Pricing Analysis and Price Dynamics
5. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Familial (hereditary) ATTR-CM*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Wild-type ATTR-CM
6. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY DRUG TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Transthyretin Stabilizers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. RNAi Therapy
6.4. Others
7. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.1.1. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Key Players
10.1.1. Pfizer Inc.*
10.1.1.1. Company Overview
10.1.1.1.1. Product Portfolio
10.1.1.1.2. Product Description
10.1.1.1.3. Product Key Performance Indicators (KPIs)
10.1.1.2. Financial Overview
10.1.1.2.1. Company Revenue
10.1.1.2.2. Geographical Revenue Shares
10.1.1.2.3. Revenue Forecasts
10.1.1.3. Key Developments
10.1.1.3.1. Mergers & Acquisitions
10.1.1.3.2. Key Product Development Activities
10.1.1.3.3. Regulatory Approvals, etc.
10.1.1.4. SWOT Analysis
10.1.2. Ionis Pharmaceuticals, Inc.
10.2. Emerging Players
10.2.1. Arrowhead Pharmaceuticals Inc.
10.2.2. Intellia Therapeutics, Inc.(LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 7 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 9 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 15 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 23 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 27 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Pfizer Inc.: Overview
Table 34 Pfizer Inc.: Product Portfolio
Table 35 Pfizer Inc.: Key Developments
Table 36 Ionis Pharmaceuticals, Inc.: Overview
Table 37 Ionis Pharmaceuticals, Inc.: Product Portfolio
Table 38 Ionis Pharmaceuticals, Inc.: Key Developments
Table 1 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 7 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 9 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 14 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 15 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 18 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 19 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 23 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 26 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 27 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Pfizer Inc.: Overview
Table 34 Pfizer Inc.: Product Portfolio
Table 35 Pfizer Inc.: Key Developments
Table 36 Ionis Pharmaceuticals, Inc.: Overview
Table 37 Ionis Pharmaceuticals, Inc.: Product Portfolio
Table 38 Ionis Pharmaceuticals, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 4 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 7 Familial (hereditary) ATTR-CM Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 8 Wild-type ATTR-CM Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 10 Transthyretin Stabilizers Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 11 RNAi Therapy Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 12 Others Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 14 Hospital Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 15 Retail Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 16 Online Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 18 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 19 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 20 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 21 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 22 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 23 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 24 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 25 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 26 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 27 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 28 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 29 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 30 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 31 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 32 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 33 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 34 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 35 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 36 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 37 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 38 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 39 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 40 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 41 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 42 Pfizer Inc.: Financials
Figure 43 Ionis Pharmaceuticals, Inc.: Financials
Figure 1 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 4 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 7 Familial (hereditary) ATTR-CM Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 8 Wild-type ATTR-CM Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 10 Transthyretin Stabilizers Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 11 RNAi Therapy Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 12 Others Drug Type in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 14 Hospital Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 15 Retail Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 16 Online Pharmacies Distribution Channel in Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 18 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 19 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 20 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 21 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 22 North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 23 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 24 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 25 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 26 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 27 Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 28 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 29 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 30 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 31 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 32 Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 33 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 34 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 35 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 36 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 37 South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Country, 2024 & 2033 (%)
Figure 38 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Value, 2022-2033 (US$ Billion)
Figure 39 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Type, 2024 & 2033 (%)
Figure 40 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Drug Type, 2024 & 2033 (%)
Figure 41 Middle East and Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 42 Pfizer Inc.: Financials
Figure 43 Ionis Pharmaceuticals, Inc.: Financials
